Table 2.
Potential targets for anti-NETs in cancer
| Target molecules | Mechanism | Agents | Cancer type | References |
|---|---|---|---|---|
| NETs components | ||||
| DNA | DNA Degradation | Recombinant DNase | CRC | [114, 115] |
| NE | NE inhibitor | GW311616 | Leukemia | [116] |
| MPO | MPO inhibitor | PF-1355, ABAH, TX1 | – | [54, 117] |
| PAD4 | PAD4 inhibitor | GSK484, Cl-amidine | PDAC | [71, 118] |
| Chemokines | ||||
| CXCR1 | CXCR1 inhibitor | SX-682, Reparixin | HNSCC, BC | [113, 119] |
| CXCR2 | CXCR2 inhibitor | SX-682, Reparixin, SB225002, AZ13381758 | HNSCC, BC, PDAC | |
| IL-8 | Anti-IL-8 | HuMab 10F8 | – | [122] |
| IL-17 | Anti-IL-17 | IL17 blockade | PDAC | [111] |
| Transmembrane DNA receptor | ||||
| CCDC25 | Anti-CCDC25 | Anti-CCDC25 antibody | BC | [85] |
| Cytokines | ||||
| TLR4 | TLR4 inhibitor | TAK-242 | CRC | [123] |
| TLR9 | TLR9 inhibitor | Hydroxychloroquine | – | [124] |
| TGF-β | TGF-β inhibitor | SB525334 | PDAC | [125] |
NETs Neutrophil extracellular traps; HNSCC Head and neck squamous cell carcinoma; CRC Colorectal cancer; PDAC Pancreatic ductal adenocarcinoma; BC Breast cancer; NE Neutrophil elastase; MPO Myeloperoxidase; PAD4 Peptidyl-arginine deiminase-4; CXCR C-X-C motif chemokine receptor; IL Interleukin; TLR Toll-like receptor; TGF-β Transforming growth factor-β